- Data from Phase 1/2 EPCORE™ NHL-1 study show patients treated with epcoritamab experienced 82% overall response rates (ORR) including 63% complete response (CR) rates as presented at the 65th...

Open Networking & Edge Summit extends speaking submission deadline to allow extra time for submissions on latest innovation across AI, Cloud Native Networking, and more 2024 industry predictions...

On December 8, the 2023 Shenzhen Global Investment Promotion Conference was held in Shenzhen, China. Over 380 projects were signed, with a total investment of 1 trillion yuan. The event was...

From December 5th to 6th, 2023 World Automotive Chip Innovation Conference & 2023 China Automotive Chip Summit was held in Binhu District, Wuxi, E China. The conference focused on cutting-edge...

With 5.6 months of additional follow-up and 78.3% of patients having completed Kisqali® (ribociclib) investigational treatment, the updated analysis shows sustained iDFS benefit and stability in...